vs
Indivior Pharmaceuticals, Inc.（INDV）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
Indivior Pharmaceuticals, Inc.的季度营收约是ROGERS CORP的1.8倍（$357.0M vs $200.5M），Indivior Pharmaceuticals, Inc.净利率更高（28.9% vs 2.2%，领先26.6%），ROGERS CORP自由现金流更多（$1.1M vs $-245.0M）
Indivior是一家全球专科制药企业，专注于开发和商业化针对阿片类物质使用障碍、酒精依赖及相关精神健康疾病的循证治疗方案，核心市场覆盖北美与欧洲，旗下多款获批疗法服务于医疗需求未被充分满足的患者群体。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
INDV vs ROG — 直观对比
营收规模更大
INDV
是对方的1.8倍
$200.5M
净利率更高
INDV
高出26.6%
2.2%
自由现金流更多
ROG
多$246.1M
$-245.0M
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $357.0M | $200.5M |
| 净利润 | $103.0M | $4.5M |
| 毛利率 | 82.1% | 32.2% |
| 营业利润率 | 22.7% | — |
| 净利率 | 28.9% | 2.2% |
| 营收同比 | — | 5.2% |
| 净利润同比 | 390.5% | 421.4% |
| 每股收益（稀释后） | $0.79 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INDVROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $357.0M | $201.5M | ||
| Q3 25 | $314.0M | $216.0M | ||
| Q2 25 | $302.0M | $202.8M | ||
| Q1 25 | $266.0M | $190.5M | ||
| Q4 24 | — | $192.2M | ||
| Q3 24 | $307.0M | $210.3M | ||
| Q2 24 | $299.0M | $214.2M |
净利润INDVROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $103.0M | $4.6M | ||
| Q3 25 | $42.0M | $8.6M | ||
| Q2 25 | $18.0M | $-73.6M | ||
| Q1 25 | $47.0M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | $22.0M | $10.7M | ||
| Q2 24 | $-97.0M | $8.1M |
毛利率INDVROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 82.1% | 31.5% | ||
| Q3 25 | 73.2% | 33.5% | ||
| Q2 25 | 82.8% | 31.6% | ||
| Q1 25 | 83.1% | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | 78.5% | 35.2% | ||
| Q2 24 | 73.6% | 34.1% |
营业利润率INDVROG
| Q1 26 | — | — | ||
| Q4 25 | 22.7% | 3.5% | ||
| Q3 25 | 13.7% | 7.3% | ||
| Q2 25 | 23.8% | -33.3% | ||
| Q1 25 | 24.8% | -0.2% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | 11.4% | 6.9% | ||
| Q2 24 | -39.5% | 5.3% |
净利率INDVROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 28.9% | 2.3% | ||
| Q3 25 | 13.4% | 4.0% | ||
| Q2 25 | 6.0% | -36.3% | ||
| Q1 25 | 17.7% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | 7.2% | 5.1% | ||
| Q2 24 | -32.4% | 3.8% |
每股收益（稀释后）INDVROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.79 | $0.20 | ||
| Q3 25 | $0.33 | $0.48 | ||
| Q2 25 | $0.14 | $-4.00 | ||
| Q1 25 | $0.38 | $-0.08 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | $0.16 | $0.58 | ||
| Q2 24 | $-0.72 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.0M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-98.0M | $1.2B |
| 总资产 | $1.2B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INDVROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $195.0M | $197.0M | ||
| Q3 25 | $445.0M | $167.8M | ||
| Q2 25 | $510.0M | $157.2M | ||
| Q1 25 | $373.0M | $175.6M | ||
| Q4 24 | — | $159.8M | ||
| Q3 24 | — | $146.4M | ||
| Q2 24 | — | $119.9M |
股东权益INDVROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-98.0M | $1.2B | ||
| Q3 25 | $-207.0M | $1.2B | ||
| Q2 25 | $-257.0M | $1.2B | ||
| Q1 25 | $-285.0M | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | $-310.0M | $1.3B | ||
| Q2 24 | $-281.0M | $1.3B |
总资产INDVROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-221.0M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $-245.0M | $1.1M |
| 自由现金流率自由现金流/营收 | -68.6% | 0.5% |
| 资本支出强度资本支出/营收 | 6.7% | 2.3% |
| 现金转化率经营现金流/净利润 | -2.15× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $-93.0M | $70.1M |
8季度趋势，按日历期对齐
经营现金流INDVROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-221.0M | $46.9M | ||
| Q3 25 | $-39.0M | $28.9M | ||
| Q2 25 | $158.0M | $13.7M | ||
| Q1 25 | $75.0M | $11.7M | ||
| Q4 24 | — | $33.7M | ||
| Q3 24 | $2.0M | $42.4M | ||
| Q2 24 | $88.0M | $22.9M |
自由现金流INDVROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-245.0M | $42.2M | ||
| Q3 25 | $-59.0M | $21.2M | ||
| Q2 25 | $141.0M | $5.6M | ||
| Q1 25 | $70.0M | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | $-5.0M | $25.2M | ||
| Q2 24 | $84.0M | $8.8M |
自由现金流率INDVROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | -68.6% | 20.9% | ||
| Q3 25 | -18.8% | 9.8% | ||
| Q2 25 | 46.7% | 2.8% | ||
| Q1 25 | 26.3% | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | -1.6% | 12.0% | ||
| Q2 24 | 28.1% | 4.1% |
资本支出强度INDVROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 6.7% | 2.3% | ||
| Q3 25 | 6.4% | 3.6% | ||
| Q2 25 | 5.6% | 4.0% | ||
| Q1 25 | 1.9% | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 2.3% | 8.2% | ||
| Q2 24 | 1.3% | 6.6% |
现金转化率INDVROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | -2.15× | 10.20× | ||
| Q3 25 | -0.93× | 3.36× | ||
| Q2 25 | 8.78× | — | ||
| Q1 25 | 1.60× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.09× | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
ROG
暂无分部数据
